Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated poliovirus vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Inactivated poliovirus vaccine (IPV) is a sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett), grown in Vero cells or monkey kidney cells and inactivated with formaldehyde. Developed by Jonas Salk in the 1950s, IPV is used to provide immunity against poliomyelitis, a highly infectious viral disease that can cause irreversible paralysis. Unlike the oral polio vaccine (OPV), IPV does not contain live virus and therefore cannot cause vaccine-associated paralytic poliomyelitis (VAPP). It is primarily administered via intramuscular or subcutaneous injection and is a core component of childhood immunization schedules globally to prevent the transmission and clinical manifestation of the poliovirus.
- Brand names
- IMOVAX POLIOIPOL
- Other names
- IPVSalk vaccineinactive poliovirus vaccinepoliomyelitis vaccine (inactivated)
02
Targets
PV-D-BCR (Naïve B-cell receptor specific for poliovirus D-antigen)CD4+ T-cell receptor recognizing poliovirus capsid-derived peptidesPV-TCR (Poliovirus capsid-specific CD8+ T-cell receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated poliovirus vaccine.